{"id":135808,"date":"2022-11-08T02:55:54","date_gmt":"2022-11-08T07:55:54","guid":{"rendered":"https:\/\/44.250.171.167\/?p=135808"},"modified":"2022-11-17T09:10:07","modified_gmt":"2022-11-17T14:10:07","slug":"divis-laboratories-ltd-q2-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q2-fy23-earnings-conference-call-insights\/","title":{"rendered":"Divi&#8217;s Laboratories Ltd Q2 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Divi&#039;s Laboratories Ltd Q2 FY23 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/e1-tljnhSVM?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Divi&#8217;s Laboratories Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/DIVISLAB\/\">DIVISLAB<\/a>) Q2 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>[00:06:48] DIVISLAB stated that though global logistics scenario has improved and is seeing receding sea and air-freight costs in 2Q23, minor disruptions stemming from issues like manpower shortages continues.<\/li>\n<\/ul>\n<ul>\n<li>[00:07:12] DIVISLAB also said that prices of some base metals like lithium and iodine multiplied several times since last year and the company expects this trend to persist.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:11:29] Prakash Agarwal of Axis Capital asked about the custom synthesis business outlook for 2H23 and FY24. Murali K Divi MD answered that this business looked very optimistic and much better than at any given time.<\/li>\n<\/ul>\n<ul>\n<li>[00:12:57] Prakash Agarwal with Axis Capital also enquired if there will be any qualitative guidance on the GM and EBITDA margin going forward, given the volatility. Murali K Divi MD said that on margins, the material consumption remains the same at 36%.<\/li>\n<\/ul>\n<ul>\n<li>[00:16:34] Cyndrella Carvalho from JM Financial asked about the new generic launches and DMF filings, when can these launches be expected. Murali K Divi MD answered that the patent expiry of these new molecules will start from 2023 to 2025. So 2024 onwards, opportunities should be looked at.<\/li>\n<\/ul>\n<ul>\n<li>[00:24:51] Neha Manpuria of Bank of America asked about the Kakinada capex and if any progress is happening. Murali K Divi MD answered that that it stands same as of last time. There is not much movement from the government and DIVISLAB is still waiting for clearance.<\/li>\n<\/ul>\n<ul>\n<li>[00:25:27] Neha Manpuria of Bank of America enquired about the utilization in 2Q23. Murali K Divi MD replied that utilization is around 80-83%.<\/li>\n<\/ul>\n<ul>\n<li>[00:28:56] Shyam Srinivasan with Goldman Sachs asked about generic API nutraceuticals, on a low base it has grown, but on a 1-2 year CAGR it\u2019s still flat. Murali K Divi MD answered that it has nothing to do with losing any business. The price pressures are still there. And one of DIVIS\u2019 competitors is leaving the business and in that case DIVIS will have a large chunk.<\/li>\n<\/ul>\n<ul>\n<li>[00:30:31] Sameer Baisiwala of Morgan Stanley enquired about the custom synthesis new projects, what\u2019s the size of these opportunities. Murali K Divi MD said that it believes it\u2019s not the size of COVID drugs, but are big compounds.<\/li>\n<\/ul>\n<ul>\n<li>[00:35:51] Sameer Baisiwala of Morgan Stanley asked about the update on the Sartan opportunity. Murali K Divi MD clarified that DIBVISLAB has become stronger as the company is the only entity to be backward integrated in it.<\/li>\n<\/ul>\n<ul>\n<li>[00:37:56] Tushar Manudhane from Motilal Oswal asked about the capacity utilization of nutraceutical business. Murali K Divi MD replied that the company is about 80% on the nutraceutical utilization, with whatever capacity that\u2019s been doubled over past one year.<\/li>\n<\/ul>\n<ul>\n<li>[00:44:36] Surya Patra of PhillipCapital asked about the new units created over the last 2 year period, how many units are currently under manufacturing. Murali K Divi MD answered that most of the units have already commenced. Two units; small volume high potency compound is under completion and another block for commercial. \u00a0Other than these two, all are done.<\/li>\n<\/ul>\n<ul>\n<li>[00:51:18] Ritwik Sheth from One-Up Financial enquired about Kakinada capex, what\u2019s the timeline in terms of starting and commissioning, assuming the govt. approval is done. \u00a0Murali K Divi MD said that once the approval is done, it should be completed in one year and start seeing the results from the second year.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Divi&#8217;s Laboratories Ltd (DIVISLAB) Q2 FY23 Earnings Concall Management Update: [00:06:48] DIVISLAB stated that though global logistics scenario has improved and is seeing receding sea and air-freight costs in 2Q23, minor disruptions stemming from issues like manpower shortages continues. [00:07:12] DIVISLAB also said that prices of some base metals like lithium and [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Divi's Laboratories Ltd Q2 FY23 Earnings Conference Call Insights #DIVISLAB #Q2 #FY23 #Earnings #Stocks","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[10304,10307,10169,1115],"class_list":["post-135808","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-api","tag-branded-drug","tag-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":129961,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":135808,"position":0},"title":"Divi&#8217;s Laboratories Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 24, 2022","format":false,"excerpt":"https:\/\/youtu.be\/MLu1npKFqZg Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q4 FY22 Earnings Concall Management Update: DIVISLAB said it reached milestone revenue for FY22 of $1 billion with decent profitability despite the hurdles faced during the pandemic. Q&A Highlights: Tushar Manudhane of Motilal Oswal asked if the company\u2019s steady-state growth of 13-15%\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":133197,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":135808,"position":1},"title":"Divi&#8217;s Laboratories Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 15, 2022","format":false,"excerpt":"https:\/\/youtu.be\/EPaxfKgyoZQ Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q1 FY23 Earnings Concall Q&A Highlights: Tushar Manudhane from Motilal Oswal asked about the stable sales in the generic side for the past 3 quarters, if capacity expansion will increase sales in coming quarters. Murali Divi MD said that with the expansion,\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":155826,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":135808,"position":2},"title":"Divi&#8217;s Laboratories Ltd Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"November 6, 2023","format":false,"excerpt":"Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q2 FY24 Earnings Concall Business Overview Anticipating growth opportunities in contrast media, sartans, soon-to-expire patented products. Demand for established generics remains stable despite pricing pressure. Pursuing comprehensive business strategy, new DMF filings to drive growth. Custom synthesis garnering customer interest with expanded capacity\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":170171,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":135808,"position":3},"title":"Divi&#8217;s Laboratories Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 14, 2025","format":false,"excerpt":"Divi\u2019s Laboratories Limited, incorporated in 1990, is engaged in the manufacture and export of Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceutical ingredients. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b92,410 crore, up 13.79% year-on-year (YoY) from \u20b92,118 crore in Q1 FY25. Total Expenses: \u20b91,796\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"DIVISLAB Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":147097,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q4-fy23-earnings-conference-call-insights\/","url_meta":{"origin":135808,"position":4},"title":"Divi&#8217;s Laboratories Ltd Q4 FY23 Earnings Conference Call Insights","author":"Praveen","date":"May 23, 2023","format":false,"excerpt":"Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q4 FY23 Earnings Concall Q&A Highlights: [00:11:30] Tushar Manudhane from Motilal Oswal asked if backward integration and softening raw material prices lead to a new normal of 57-58% GM. Murali Divi MD replied that RM prices are decreasing, stabilizing, and expected to continue\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":140018,"url":"https:\/\/alphastreet.com\/india\/divis-labs-ltd-nsedivislab-q3-fy23-results-outtotal-income-rises-5-yoy\/","url_meta":{"origin":135808,"position":5},"title":"Divis Labs Ltd.(NSE:DIVISLAB )|Q3 FY23 Results Out|Total Income rises 5% yoy","author":"Divyansh_Kasana","date":"February 3, 2023","format":false,"excerpt":"Divi's Laboratories Limited (NSE: DIVISLAB) is a pharmaceutical company specializing in the manufacture of active pharmaceutical ingredients (APIs) and intermediates. The company operates globally, with facilities in India, the United States, and Europe, and serves customers in over 60 countries. Divi's Laboratories is known for its strong focus on quality\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/fa084a5e-371a-4ccb-95c8-d5eeac5c1854-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/fa084a5e-371a-4ccb-95c8-d5eeac5c1854-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/fa084a5e-371a-4ccb-95c8-d5eeac5c1854-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/fa084a5e-371a-4ccb-95c8-d5eeac5c1854-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/fa084a5e-371a-4ccb-95c8-d5eeac5c1854-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/fa084a5e-371a-4ccb-95c8-d5eeac5c1854-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/135808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=135808"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/135808\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=135808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=135808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=135808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}